Allorion Therapeutics inks $40m Series A

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, has secured $40 million in Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this